In the field of anti-aging, NAD+ (Nicotinamide Adenine Dinucleotide) is undoubtedly the most closely watched core molecule. Known as the "energy currency" within cells, it participates in almost all critical life processes—from basic energy metabolism to DNA damage repair, from immune regulation to the activation of longevity proteins Sirtuins.
As we age, NAD+ levels in the human body decline precipitously, a change closely linked to the aging process and the development of multiple chronic diseases. To effectively replenish NAD+, scientists have developed various precursor substances—they act as "raw materials" for manufacturing NAD+, which enter the body and undergo a series of metabolic reactions to eventually convert into active NAD+.
Currently, the three mainstream NAD+ precursor supplements on the market are Nicotinamide (Nam), Nicotinamide Riboside (NR), and Nicotinamide Mononucleotide (NMN), all belonging to the vitamin B3 family. However, there has been ongoing debate about which one offers better efficacy and value for money. It was not until recently that Nature Metabolism published a groundbreaking study that completed the first direct head-to-head comparison of the three precursors in healthy humans, providing the most conclusive answer.
First, Why Do We Need to Supplement NAD+ Precursors?
NAD+ itself is a large molecule that cannot be directly absorbed and utilized by the human body, so we can only indirectly increase its levels by supplementing its precursors. Over the course of evolution, the human body has developed three pathways for synthesizing NAD+: the de novo synthesis pathway, the Preiss-Handler pathway, and the salvage pathway. Different precursors follow distinct metabolic routes, which determines their ultimate efficacy.
For modern people, relying solely on daily diet is no longer sufficient to maintain adequate NAD+ levels. On the one hand, naturally occurring NAD+ precursors in food are present in extremely low concentrations; on the other hand, factors such as aging, excessive stress, staying up late, and alcohol consumption all accelerate NAD+ depletion. This is why NAD+ supplements have become a popular choice in the anti-aging field.
A Fair Competition: How Rigorous Is the Study Design?
This study, led by the Amsterdam University Medical Centers in the Netherlands, adopted the gold standard for clinical research—a randomized, double-blind, placebo-controlled, four-arm parallel trial design—ranking among the most rigorous and authoritative studies in the field.
A total of 65 healthy adults aged 18 to 50 were enrolled and randomly assigned to four groups, taking the corresponding supplement once daily for 14 consecutive days:
- Nicotinamide (Nam) group: 500 mg daily
- Nicotinamide Riboside (NR) group: 1000 mg daily
- Nicotinamide Mononucleotide (NMN) group: 1000 mg daily
- Placebo group: Equal amount of placebo daily
The researchers used the most precise liquid chromatography-tandem mass spectrometry (LC-MS/MS) technology to comprehensively measure the concentrations of NAD+ and its related metabolites in whole blood, plasma, and urine of the subjects on day 1 and day 14 of supplementation, evaluating both acute responses (within 4 hours after dosing) and chronic effects (after 14 consecutive days of intake).
Core Finding 1: Long-Term Efficacy: NR and NMN Perform Equally Well, Nam Surprisingly Falls Short
The results of 14 consecutive days of supplementation completely overturned many people's traditional understanding of these three precursors:
- NR and NMN have comparable efficacy: Both increased whole blood NAD+ concentrations by approximately 2-fold, with an average increase of 49.4 μM in the NR group and 43.1 μM in the NMN group, showing no statistically significant difference between the two.
- Nam cannot elevate basal NAD+ levels: As the earliest form of vitamin B3 used, nicotinamide performed the worst in this study. After 14 consecutive days of supplementation, there was no statistically significant increase in the subjects' basal NAD+ levels.
This result clearly indicates that in healthy adults, NR and NMN are superior choices for long-term NAD+ elevation, while traditional nicotinamide is far less effective in this regard.
Core Finding 2: Dramatic Differences in Acute Effects Reveal Underlying Mechanisms
In terms of acute responses, the three precursors exhibited strikingly different characteristics:
- Nam: Fast onset, short duration: It is rapidly absorbed within 1 hour after oral administration, causing a sharp spike in whole blood nicotinamide concentration and a transient increase in NAD+ levels. However, this effect is extremely short-lived, accompanied by the production of large amounts of the metabolic waste N1-methylnicotinamide (MeNam), indicating that most Nam is rapidly metabolized and excreted without being effectively utilized.
- NR and NMN: No acute effect, more sustained efficacy: Within the 4-hour observation window after dosing, neither caused an acute increase in NAD+ levels. But this does not mean they are ineffective; on the contrary, this delayed onset characteristic suggests they follow a completely different metabolic pathway.
Key Discovery: Gut Microbiota Are the Unsung Heroes of NAD+ Elevation
Why do NR and NMN show no acute effects but have better long-term efficacy? Through in vitro fecal fermentation experiments, the researchers finally solved this mystery—gut microbiota are the core link for NR and NMN to exert their effects.
The experimental results showed:
- Human gut microbiota can first convert NR and NMN into nicotinamide (Nam), and then deamidate it into nicotinic acid (NA) via the bacterial-specific enzyme PncA.
- The produced nicotinic acid is then absorbed by the human body and enters tissues such as the liver to synthesize NAD+ through the more efficient Preiss-Handler pathway, which is why they can achieve long-term stable NAD+ elevation.
- In contrast, nicotinamide is poorly converted to nicotinic acid by gut microbiota. Most of it is directly absorbed into the bloodstream in the proximal small intestine and follows the hepatic salvage pathway. While this pathway is fast, it has a significant saturation effect, and excess nicotinamide can only be rapidly metabolized and excreted without being effectively converted into NAD+.
Unexpected Bonus: Beyond NAD+ Elevation, Improved Gut Health
This study also discovered a previously overlooked important benefit of NR and NMN: regulating gut microbiota metabolism.
During the conversion of NR and NMN to nicotinic acid, the metabolic activity of gut microbiota is significantly enhanced, leading to a marked increase in the production of total short-chain fatty acids (SCFAs). SCFAs are the "gold standard" for gut health, with multiple important roles including anti-inflammation, maintaining intestinal barrier integrity, and regulating immune function.
This effect has been verified in fecal samples from healthy adults, the elderly, and even patients with Crohn's disease, showing good universality. In other words, supplementing with NR and NMN can achieve a "two birds with one stone" effect: not only elevating systemic NAD+ levels over the long term but also indirectly promoting gut health by improving gut microbiota metabolism.
Summary and Outlook
This groundbreaking study published in Nature Metabolism is the first to systematically elucidate the metabolic differences among the three major NAD+ precursors in humans, pushing gut microbiota to the center stage of NAD+ supplementation. It tells us that NAD+ elevation is far from a simple "you get what you eat" process, but the result of the precise collaboration between the host and gut microbiota.
Of course, the study also has certain limitations: it only targeted healthy adults and did not include the elderly or patients with chronic diseases; the observation period was short, and long-term safety and efficacy still need further verification. Nevertheless, it undeniably provides the most authoritative scientific basis for our choice of NAD+ supplements.
In the future, the development of NAD+ supplementation will become more precise: on the one hand, developing novel precursors with higher bioavailability (current data shows that some novel proprietary NAD+ precursors can achieve an elevation efficiency more than 3 times that of traditional NMN); on the other hand, personalized supplementation regimens based on individual gut microbiota characteristics are expected to become a new trend in the anti-aging field.